Indian Gooseberry (Expanded) for Blood Sugar Regulation

Research suggests that Indian gooseberry (amla, Phyllanthus emblica) may support blood sugar regulation, with evidence spanning a 2023 meta-analysis of randomized controlled trials, multiple animal studies, mechanistic reviews, and at least one RCT in prediabetic patients, all pointing in a consistently supportive direction. Studies indicate that amla supplementation has been associated with reductions in fasting blood glucose, HbA1c, insulin resistance markers, and related glycemic indicators across both human and animal models, with proposed mechanisms including modulation of hepatic glucose-regulating enzymes, antioxidant activity, and tannin-driven antidiabetic effects. A 2025 human trial examining amla in combination with chromium and shilajit alongside exercise and diet showed some modest improvements in metabolic markers, though findings were mixed and some results only approached statistical significance. Reviewers and study authors consistently note meaningful limitations in the existing literature, including heavy reliance on animal and in vitro models, variability in formulations and dosing, insufficient standardization, and a need for more rigorously controlled human trials before firm clinical conclusions can be drawn.